Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Allison Berger"'
Autor:
Neil MacLean, Shawn Brennan, Adam C. Smith, Rose Hurren, Allison Berger, Xiaoming Wang, Razq Hakem, Marcela Gronda, Mark D. Minden, Sara Farshchi Zarabi, Simon Kavanagh, Tary Traore, G. Wei Xu, Aaron D. Schimmer, Emil F. Pai, Samir H. Barghout, Ondrej Halgas, Michael Milhollen, Marc L. Hyer, Parasvi S. Patel, Danny V. Jeyaraju
Publikováno v:
Leukemia. 33:37-51
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy for which new therapeutic approaches are required. One such potential therapeutic strategy is to target the ubiquitin-like modifier-activating enzyme 1 (UBA1), the initiating enzyme
Publikováno v:
Leukemialymphoma. 60(12)
With the advent of proteasome inhibitors (bortezomib) and pleiotropic pathway modulators which target cereblon E3 ligase (lenalidomide), the ubiquitin-proteasome system has emerged as a tractable target in non-Hodgkin lymphoma and multiple myeloma. H
Autor:
Craig Okada, Alexey V. Danilov, Nur Bruss, Allison Berger, Cody Paiva, Tingting Liu, Adam Kittai, Scott R Best, Taylor Hashiguchi
Publikováno v:
Blood advances. 3(1)
Alterations in the ubiquitin proteasome system (UPS) leave malignant cells in heightened cellular stress, making them susceptible to proteasome inhibition. However, given the limited efficacy of proteasome inhibitors in non-Hodgkin lymphoma (NHL), no
Autor:
Adrianne L. Stefanski, Tomasz Sosinowski, Virginia D. Winn, Allison Berger, Nathan D. Pennock, Leonard L. Dragone, Lisa K. Peterson, Eric Treacy, Samantha Friend
Publikováno v:
PLoS ONE
PLoS ONE, Vol 8, Iss 10, p e75200 (2013)
PLoS ONE, Vol 8, Iss 10, p e75200 (2013)
While neddylation is known to activate cullin (CUL)-RING ubiquitin ligases (CRLs), its role in regulating T cell signaling is poorly understood. Using the investigational NEDD8 activating enzyme (NAE) inhibitor, MLN4924, we found that neddylation neg